The field of cancer immunotherapy has evolved dramatically in recent years. As increasingly greater options for, and combinations of, cancer immunotherapy become available, clinicians need to stay up-to-date on the role of immunotherapy in a rapidly changing therapeutic landscape.

Although there is general agreement on the importance and benefits of early integration of palliative care in oncology, timely and seamless integration remains a major challenge.

Immunotherapy-related toxicity impacts the majority of patients receiving cancer immunotherapy, and a significant proportion of patients experience higher-grade immune-related adverse events (irAEs).

With the improved effectiveness of cancer treatment, more and more patients are surviving longer and may experience fractures as a long-term complication of bone loss.

Despite the high rate of complete remission for patients with ALL, a majority of patients will develop relapsed or refractory disease. Recent advances expanding available therapeutic options could change the standard of care for these patients.

Case managers and medical directors need to have wide-ranging knowledge about how solid tumors are managed so that they can help patients with solid tumors coordinate their care among different specialists (e.g., diagnostic radiology, medical oncology, palliative care).